

DRUG NAME: Interferon alfa-2b**SYNONYM(S):** IFN, alpha interferon**COMMON TRADE NAME(S):** INTRON-A®**CLASSIFICATION:** biological response modifier,¹ cytotoxic²*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Interferons bind to receptors on the cell surface and initiate a cascade of intracellular events, including induction of certain enzymes.¹ This leads to various cellular responses, including inhibition of virus replication, suppression of cell proliferation, enhancement of macrophage activity, and augmentation of the specific cytotoxicity of lymphocytes. Interferon does not appear to be cell-cycle specific.

PHARMACOKINETICS:

Interpatient variability	substantial variability has been observed ³	
Absorption	IM: 83%; SC: 90%	
	intralesional: not specifically defined, but approximately 1/3 that of IM/SC ³	
	time to peak plasma concentration	IM,SC: 3-12 h intralesional ³ : 6 h
Distribution	widely distributed, but not concentrated in any particular organ ³	
	cross blood brain barrier?	no
	volume of distribution	31 L (may be 370-720 L with continuous infusion)
	plasma protein binding	no information found
Metabolism	mainly renal ^{3,4} ; hepatic metabolism minor ⁴	
	active metabolite(s)	no information found
	inactive metabolite(s)	no information found
Excretion	mainly catabolism, renal secretion ⁴ ; biliary excretion minor ³	
	urine	trace amounts excreted in urine
	feces	no information found
	terminal half life	IV,IM: 2 h; SC: 3 h (may be up to 29 hours in patients with disseminated cancer) ³
	clearance ⁵	231 mL/h/kg
Gender	no information found	
Elderly	no information found	
Children	no information found	
Ethnicity	no information found	

Adapted from standard reference⁶ unless specified otherwise.**USES:****Primary uses:**

* Basal cell cancer

Other uses:Carcinoid tumour³

Bladder cancer	Cervical cancer ^{3,6}
* Kaposi's sarcoma, AIDS-related	Essential thrombocythemia ⁷
* Leukemia, chronic myelogenous (CML)	Lymphoma, cutaneous T-cell ³
* Leukemia, hairy cell	Ovarian cancer ³
* Lymphoma, non-Hodgkin's	Polycythemia vera ⁶
* Melanoma	Squamous cell cancer ^{3,6}
* Multiple myeloma	Thyroid cancer ⁶
Renal cell cancer	
* Thrombocytosis associated with CML	

*Health Canada approved indication

SPECIAL PRECAUTIONS:

Contraindicated in patients who have a history of hypersensitivity to any interferon.¹

Caution in patients with¹:

- creatinine clearance < 50 mL/min
- a psychiatric condition or history of severe psychiatric disorder
- autoimmune disease
- myelosuppression
- decompensated liver disease
- organ transplant (preliminary data indicates increased rate of graft rejection)
- hypertriglyceridemia
- psoriatic disease and sarcoidosis
- coagulation disorders
- severe pre-existing heart disease
- debilitating medical conditions (e.g., cardiovascular disease, pulmonary disease, diabetes) because of fever and other "flu-like" symptoms
- seizure disorders, brain metastases, or compromised CNS function⁶

Kaposi's sarcoma, AIDS-related: Do not use in patients with rapidly progressive visceral disease.¹ These patients require rapid cytoreduction, while the response to interferon is slow and poor.³

Carcinogenicity: studies have not been performed¹

Mutagenicity: not mutagenic¹

Fertility: Decreased serum estradiol and progesterone levels have been reported in women.¹ Menstrual cycle abnormalities and abortions have been reported in animals.

Pregnancy: FDA Pregnancy Category C.⁶ Animal studies have shown fetal risks and there are no controlled studies in women. Interferon should be given only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding is not recommended due to the potential secretion into breast milk.⁶

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.⁸

ORGAN SITE	SIDE EFFECT	ONSET			
Clinically important side effects are in bold, italics I = immediate (onset in hours to days); E = early (days to weeks); D = delayed (weeks to months); L = late (months to years)					
allergy/immunology	acute hypersensitivity reactions (<5%); ⁶ urticaria, angioedema, bronchoconstriction, anaphylaxis	I			
	antibody production to interferon (0-30%); highly variable, questionable clinical significance ³		E		
	vasculitis (<5%) ⁶		E		
auditory/hearing	hearing disorder (rare)			D	
blood/bone marrow/ febrile neutropenia	myelosuppression ^{3,6} : onset 7-10 d, nadir 14 d, recovery 21 d; leucopenia onset may be within hours, nadir may be 22-38 d; neutropenia (30-70%); anemia (15-65%) usually only during first six months of therapy; thrombocytopenia (5-70%)		E ⁶		
	hemolytic anemia (up to 10%) ⁶		E		
cardiovascular (arrhythmia)	arrhythmia (<5%) ⁶		E		
cardiovascular (general)	angina pectoris, myocardial infarction (<5%) ⁶		E		
	hypertension (9%) ⁶		E		
	hypotension, related to fluid depletion (up to 9%) ³		E		
	peripheral edema (up to 9%) ³		E		
coagulation	thrombocytopenic purpura (<5%) ⁶		E		
constitutional symptoms	chills (40-65%), ³ rigors (2-42%) ⁶	I			
	diaphoresis (2-21%) ⁶	I			
	fatigue/malaise (50-95%), ³ asthenia (less common)	I			
	fever (40-98%) ³	I			
	malignant hyperpyrexia (very rare)		E		
	weight loss (up to 25%), ³ cachexia (<1%) ³			D	
dermatology/skin	<i>extravasation hazard: none</i>				
	alopecia (8-38%) ⁶		E		
	dry skin (1-10%) ⁶		E		
	erythema multiforme (rare)		E		
	injection site reaction (1-20%) ⁶ ; injection site necrosis (very rare)	I	E		
	pruritis (3-11%) ⁶		E		
	rash (1-25%) ⁶		E		
	Stevens-Johnson syndrome, toxic epidermal necrolysis (<5%) ⁶		E		
endocrine	adrenal hypercorticism (very rare)			D	
	diabetes mellitus, aggravated diabetes mellitus (very rare)			D	
	hot flashes (very rare)			D	
	hyperthyroidism or hypothyroidism (rare), not always reversible ³		E		

ORGAN SITE	SIDE EFFECT	ONSET			
Clinically important side effects are in bold, italics I = immediate (onset in hours to days); E = early (days to weeks); D = delayed (weeks to months); L = late (months to years)					
	virilism (<1%) ³			D	
gastrointestinal	<i>emetogenic potential: low to low-moderate</i>				
	<i>anorexia</i> (1-69%) ⁶		E	D	
	constipation (1-14%) ⁶		E		
	<i>diarrhea</i> (2-45%, may be severe) ⁶		E		
	dyspepsia (2-8%) ⁶		E		
	gingivitis (2-14%) ⁶		E	D	
	<i>nausea</i> (19-66%) ⁶		E		
	pancreatitis (<5%) ⁶		E	D	
	stomatitis (up to 6%) ³		E		
	taste alteration (2-24%) ⁶		E		
	<i>vomiting</i> (6-50%) ³		E		
	xerostomia (1-28%) ⁶		E		
hemorrhage	epistaxis (rare)		E	D	
	gastrointestinal hemorrhage (<5%) ⁶		E	D	
	hemoptysis (<5%) ⁶		E	D	
	retinal hemorrhage (rare)		E	D	
	uterine/vaginal hemorrhage (very rare)		E	D	
hepatic	<i>fatal hepatotoxicity</i> (rare)		E	D	
	hepatic encephalopathy (very rare)		E	D	
infection	herpes simplex (rare)		E		
	viral infection (rare)		E		
	fungal infection, moniliasis, sepsis (very rare)		E		
metabolic/laboratory	<i>elevated alkaline phosphatase</i> (48%), <i>transaminases</i> (up to 63% for AST) ⁶		E	D	
	hyperglycemia (33-39%) ⁶		E	D	
	hypertriglyceridemia (rare, but sometimes severe)		E	D	
	hyperuricemia (15%) ³		E		
	hypocalcemia (10-51%) ⁶		E	D	
	increased creatinine, BUN (up to 10%) ³		E	D	
	proteinuria (15-20%), ³ nephrotic syndrome (<5%) ⁶		E	D	
musculoskeletal	myositis, rhabdomyolysis (rare)				
	<i>weakness</i> (5-63%) ⁶		E		
neurology	<i>alteration of mental status</i> (1-17%); encephalopathy, coma (<1%) ³			D	
	amnesia (1-14%) ⁶			D	

ORGAN SITE	SIDE EFFECT	ONSET			
<p style="text-align: center;">Clinically important side effects are in bold, italics I = immediate (onset in hours to days); E = early (days to weeks); D = delayed (weeks to months); L = late (months to years)</p>					
	anxiety (1-9%) ⁶		E	D	
	ataxia (<5%) ⁶			D	
	stroke (<5%) ⁶			D	
	confusion (1-12%) ⁶			D	
	depression (4-40%) ⁶			D	
	dizziness (7-40%), ^{3,6} vertigo (8%), ⁶ syncope (<5%) ⁶		E	D	
	emotional lability (<5%) ³		E	D	
	extrapyramidal symptoms (<5%) ⁶			D	
	impaired concentration (1-14%) ⁶			D	
	irritability (1-22%) ⁶		E	D	
	mania (<5%) ⁶		E	D	
	nervousness (1-3%) ⁶		E	D	
	paresthesia (1-21%) ⁶			D	
	psychosis, including hallucinations (<5%) ⁶			D	
	seizures (<5%) ⁶			D	
	sleep disturbance: insomnia (1-12%) ⁶ or somnolence (1-33%) ⁶		E	D	
speech disorder (aphasia >5%) ⁶			D		
suicidal ideation, suicide attempts, suicide (<5%) ⁶			D		
ocular/visual	ocular changes (rare); see discussion following table			D	
pain	abdominal pain (2-23%) ⁶		E		
	arthralgia (5-24%) ³	I			
	back pain (1-19%) ⁶		E		
	chest pain (2-28%) ⁶		E		
	headache (20-70%) ³	I			
	musculoskeletal pain (1-21%) ⁶		E		
	myalgia (30-75%) ³	I			
other body pains (3-15%) ⁶		E			
pulmonary/upper respiratory	bronchospasm (<5%) ⁶		E		
	cough (1-31%) ⁶		E		
	dyspnea (1-34%) ⁶		E		
	pharyngitis (1-31%) ⁶		E		
	nasal congestion (1-10%) ⁶		E		
	pulmonary embolism (<5%) ⁶		E		
	pulmonary fibrosis (<5%) ⁶		E		
renal/genitourinary	renal failure (<5%) ⁶			D	

ORGAN SITE	SIDE EFFECT	ONSET			
Clinically important side effects are in bold, italics I = immediate (onset in hours to days); E = early (days to weeks); D = delayed (weeks to months); L = late (months to years)					
sexual/reproductive function	decreased libido (1-5%) ⁶				D
	impotence (up to 6%, transient) ³				D
	gynecomastia (<5%) ³				D
	menstrual disorders (generally rare, up to 12% in lymphoma ⁶)				D
syndromes	flu-like syndrome (98%) ³	I			
	lupus erythematosus (<5%) ⁶				D
vascular	thrombosis (<5%) ⁶		E		

Adapted from standard reference¹ unless specified otherwise.

In general, almost all patients experience at least one side effect during interferon therapy.^{1,3} Most are mild to moderate in severity, diminish with continued use, and may be decreased by administering interferon at bedtime.³ However, discontinuation of therapy due to side effects may be required in 3-24% of patients.^{1,3}

“Flu-like” symptoms are the most commonly reported side effects of interferon, and usually include fever, fatigue, headache, and myalgia.¹ Other symptoms may include chills, arthralgia, rigors, tachycardia, anorexia, dry mouth, taste alteration, back pain, sweating, dizziness, abdominal cramps, and diarrhea. While the symptoms develop in almost all patients, the severity of symptoms seems to be dose-related.³

Fever may be due to a drug-related release of hypothalamic prostaglandin (PGE₂), rather than an increase in interleukin-1. Fever may reach 40°C within 6 hours, and may last 2-12 hours if untreated.³ Pretreatment with acetaminophen is recommended: 500-1000 mg 30 minutes before interferon (maximum 4 g daily).¹ To properly assess the source of fever, adjunctive acetaminophen should be limited to 5 consecutive days unless otherwise specified by the prescriber.

Fatigue might be distinct from the flu-like syndrome.³ In some cases, a persistent and pervasive fatigue continues throughout treatment. This type of fatigue has been postulated to result from a neurotoxic effect of interferon. It may be accompanied by lassitude, lack of motivation, or psychomotor retardation, and may necessitate a dose reduction or discontinuation of therapy.

Hypotension due to fluid depletion may occur.³ Patients should be counselled to maintain adequate hydration throughout therapy. Hypotension may be treated with fluid replacement, although hypotension that develops gradually during therapy may not respond to this maneuver. Severe hypotension that occurs during administration or within 2 days of interferon treatment may require dose reduction or discontinuation of therapy, in addition to supportive therapy.

Ocular changes such as retinopathy, retinal hemorrhage, cotton wool spots, retinal artery or vein obstruction, loss of visual acuity or visual field, optic neuritis, and papilledema may rarely occur.¹ A baseline eye examination is recommended for patients with diabetes mellitus or hypertension.³ Any patient complaining of ocular symptoms, including loss of visual acuity or visual field, must have a prompt and complete eye examination.¹ Discontinuation of interferon should be considered.

Neurologic side effects are numerous. Fatigue, headache, dizziness, and malaise have been described above as part of a “flu-like syndrome.” Depression, paresthesias, pain, altered mental status, sleep disturbances, anxiety, and emotional lability may also occur.³ Risk factors may include older age, high doses, and underlying CNS impairment. Patients and their families should be aware that many of these side effects develop insidiously, and may present as problems at work or trouble with interpersonal relationships. Various EEG abnormalities have been reported, but the mechanism of CNS dysfunction has not yet been elucidated; neurotransmitters may be involved to some extent, since metoclopramide and methylphenidate have occasionally been effective. In most cases, counselling and

reassurance is the treatment of choice. Pharmacologic treatment (e.g., antidepressants, anxiolytics) may be given symptomatically. Dose reduction or discontinuation of therapy may be required for severe or refractory cases.

Pulmonary changes such as pulmonary infiltrates, pneumonitis, and pneumonia may rarely occur.¹ These changes are reported more often in patients with chronic hepatitis C, but have been observed in oncologic diseases as well. The problem is more frequent when interferon is used concurrently with Shosaikoto or Xiao Chai Hu Tang (see Drug Interactions). Any patient with new onset of fever, cough, dyspnea, or other respiratory symptoms must have a chest X-ray. If the chest X-ray shows pulmonary infiltrates, monitor the patient and discontinue interferon if appropriate. Prompt discontinuation of interferon and supportive treatment including corticosteroids are associated with resolution.

Hyperuricemia may result from cell lysis and may lead to electrolyte disturbances or acute renal failure.⁹ In general, hyperuricemia is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas and myeloproliferative diseases. The risk may be increased in patients with preexisting renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients¹⁰:

- aggressive hydration: 3 L/m²/24 hr with target urine output > 100 mL/hr
- if possible, discontinuation of drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitoring of electrolytes, calcium, phosphate, renal function, LDH and uric acid q6h x 24-48 hours
- electrolyte replacement as required
- allopurinol 600 mg po initially, then 300 mg po q6h x 6 doses, then 300 mg po daily x 5-7 days

Urine should be alkalinized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH > 7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalinization of the urine.¹¹ It may be used for treatment or prophylaxis of hyperuricemia, 0.2 mg/kg IV daily for up to 7 days;^{11,12} however, its place in therapy has not yet been established.

Cardiotoxicity, particularly arrhythmia, seems to be correlated with preexisting cardiovascular disease and prior cardiotoxic therapy.¹ Rarely, cardiomyopathy has been reported in patients without prior cardiac disease; this may be reversible upon discontinuation of interferon.

Side effects from **intralesional administration** of interferon are similar to those observed with systemic use, and can include leucopenia, thrombocytopenia, and elevated liver enzymes.¹ However, these side effects are generally transient, rapidly reversible, and mild to moderate in severity.

Side effects from **intravesical administration** of interferon (into the bladder), either alone or in combination with BCG, are mild to moderate in severity, and limited to flu-like symptoms (8-17%), urinary frequency, and dysuria.¹³⁻¹⁵

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
angiotensin-converting enzyme (ACE) inhibitors ¹⁶	increased risk of granulocytopenia	unknown; observed in patients treated for cryoglobulinemia, so may involve autoimmunity	monitor
BCG ¹⁷	potential for decreased effect of BCG with interferon ready-to-use solution	antimicrobial preservative m-cresol may decrease viability of BCG	use only the lyophilized powder formulation of interferon when given in combination with BCG
barbiturates ³	increased levels of barbiturate and barbiturate toxicity	unknown; may be due to inhibition of CYP P450	consider decreasing dose of barbiturate
erythropoietin ^{6,18}	possible decreased effectiveness of erythropoietin	unknown; may blunt erythroid response to erythropoietin	monitor

AGENT	EFFECT	MECHANISM	MANAGEMENT
melphalan ⁶	possible decreased effectiveness of melphalan	unknown; decreased serum levels of melphalan	monitor
prednisone ⁶	possible decreased effectiveness of interferon	unknown	monitor
Sho-saiko-to (Japanese name for Xiao Chai Hu Tang) ^{1,19}	increased risk of pulmonary side effects	unknown	avoid concurrent use
theophylline ²⁰	increased levels of theophylline; more pronounced in smokers; clinical relevance unknown	inhibition of CYP 1A2 by interferon decreases metabolism of theophylline	consider decreasing dose of theophylline
warfarin ²⁰	possible increased effectiveness and toxicity of warfarin	unknown	monitor INR and adjust warfarin dose as needed
Xiao Chai Hu Tang; Chinese herbal remedy containing Bupleurum root, Pinellia tuber, Scutellaria root, ginseng, jujube, licorice, and ginger ^{1,19}	increased risk of pulmonary side effects	unknown	avoid concurrent use
zidovudine ³	increased risk of hematologic and hepatic side effects	unknown; may be additive or synergistic	monitor

SUPPLY AND STORAGE:

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

Formulations³: Various pegylated and non-pegylated formulations of recombinant and naturally-occurring interferons are available. This information is specific to recombinant interferon alfa-2b (INTRON-A®). Dose, route of administration, and adverse effects may vary among different types of interferon, as well as different formulations of the same type. Patients should be advised not to change preparations during a course of treatment.

INTRON-A® lyophilized powder with diluent¹: vials contain 10 or 18 MU interferon alfa-2b. Each vial is packaged with one vial of 10 mL SWI. Store between 2-8°C. May be stored at 45°C for up to 7 days²¹ or 25°C for up to 28 days, but cannot be returned to the refrigerator for a new storage period.

INTRON-A® Ready-To-Use solution (Albumin [human] free)¹: vials contain 10 MU interferon alfa-2b (10 MU/mL), 18 MU (6 MU/mL), or 25 MU (10 MU/mL). Solution also contains edetate disodium, m-cresol, polysorbate 80, sodium chloride, and sodium phosphate. Each vial contains overfill designed to account for loss of solution in the needle and needle hub, thereby allowing the prescribed dose to be withdrawn from the vial. Store between 2-8°C; do not freeze. May be stored at 25°C for up to 7 days. After first use, 10 MU vials are stable for 7 days at 2-8°C; 18 and 25 MU vials are stable for 28 days at 2-8°C.

INTRON-A® solution for injection (Albumin [human] free) multi-dose pen¹: pens contain 18 MU (15 MU/mL), 30 MU (25 MU/mL), or 60 MU (50 MU/mL). Solution also contains edetate disodium, m-cresol, polysorbate 80, sodium chloride, and sodium phosphate. Store between 2-8°C; do not freeze. Pens must be discarded 28 days after first use. Up to 48 hours of storage at 15-25°C is permitted during the 28 days.

Each pen contains a pre-filled multi-dose cartridge for SC administration.¹ It is designed to deliver fixed doses as required using a simple dial mechanism. Each pen contains 1.5 mL of interferon alfa-2b solution: 1.2 mL for therapeutic use and 0.3 mL of extra solution added to clear air from the needle before injection. The pen should be removed from the refrigerator approximately 30 minutes before administration to allow the solution to reach room

temperature. After each use, the needle should be discarded safely and the pen must be returned to the refrigerator immediately. Each pen is packaged with 12 Novofine 30G 8mm needles and alcohol swabs.

SOLUTION PREPARATION AND COMPATIBILITY:

Reconstitute powder with 1 mL of the accompanying SWI.¹ Bacteriostatic water for injection may be used if the patient is not allergic to benzyl alcohol. To reconstitute, direct the stream at the vial wall and not at the powder.²¹ Swirl gently to dissolve the powder. Do not shake. To obtain an isotonic solution appropriate for intralesional administration, the 10 MU vial must be reconstituted with 1 mL of the accompanying diluent.¹

Reconstituted solution for injection should be used immediately, but stability at 2-8°C has been demonstrated for 24 hours.¹ If reconstituted with bacteriostatic water for injection, solution is stable for 30 days at 2-8°C and 14 days at 15-30°C.

Diluted solution for infusion¹: Solution should be diluted in NS to a concentration ≥ 0.3 MU/mL (generally 50 mL NS). Also compatible with the following IV fluids at 0.5-1 MU/mL in glass bottles for 24 hours at room temperature or in the fridge: Ringers, Lactate Ringers, amino acid injections, 5% sodium bicarbonate.

Compatibility: no information found

Incompatibility: no information found

Additional information:

Interferon eye drops:

Interferon eye drops 1 MU/mL can be prepared with bacteriostatic water.²²

- Transfer 1 mL from a 10 MU (10 MU/mL) vial of INTRON-A® Ready-To-Use solution to a sterile 15 mL eye dropper bottle.
- Add 9 mL of bacteriostatic water to give a concentration of 1 MU/mL.

The final product is stable for 14 days refrigerated.²³⁻²⁵

PARENTERAL ADMINISTRATION:

BCCA administration guideline noted in **bold, italics**

Subcutaneous	<i>Preferred for self-administration. Rotate sites of injection.</i> ⁶
Intramuscular	May be used for self-administration. ¹ Rotate sites of injection. Avoid if patient is at risk for bleeding or is thrombocytopenic; use SC instead. ³
Direct intravenous	no information found
<i>Intermittent infusion</i>	<i>in 50 mL NS over 20 minutes, followed by 500 mL NS over 60 minutes</i>
Continuous infusion	has been used ⁶
Intraperitoneal	has been used ³
Intrapleural	no information found
Intrathecal	has been used ³
Intra-arterial	no information found
<i>Intravesical</i>	<i>in 50 mL preservative-free NS, dwell time 2 h</i>

BCCA administration guideline noted in ***bold, italics***

Intralesional	Clean lesion with sterile alcohol pad. Using a fine (30) gauge needle and a 1 mL syringe, inject into the base and substance of the lesion. Avoid SC injection. An isotonic solution for injection is recommended (see Solution Preparation and Compatibility). ¹
---------------	--

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:

BCCA usual dose noted in ***bold, italics***

Subcutaneous/intramuscular:	Cycle Length:	
	daily:	<i>CML, thrombocytosis</i> ²⁶ <i>5 MU/m²</i> (range 0.5-10 MU/m ² , to control white blood cell or platelet count) <i>SC/IM daily</i> When controlled, dosage may be administered three times weekly (tiw). ¹
	weekly:	<i>AIDS-related Kaposi's sarcoma</i> ^{1,3} <i>30 MU/m² SC/IM tiw</i>
	weekly:	<i>hairy cell leukemia</i> ^{3,6} <i>2 MU/m² SC/IM tiw</i>
	weekly:	<i>lymphoma, myeloma</i> ^{1,27} <i>3 MU (range 2-5 MU) SC/IM tiw</i>
	weekly:	<i>renal cell cancer</i> ²⁸ <i>5 MU SC tiw x 2 doses, then 10 MU SC tiw</i> (range 5-20 MU SC/IM daily or tiw) <i>for 12 weeks or until disease progression (whichever comes first)</i>
Intravenous:	weekly:	<i>melanoma</i> ²⁹ <i>induction: 20 MU/m² IV once daily for 5 consecutive days, for 4 weeks, followed by 10 MU/m² SC tiw for 48 weeks</i>
Intralesional:	weekly:	<i>basal cell cancer</i> ¹ 0.5 MU/cm ² of lesion's initial size (minimum 1.5 MU, maximum 5 MU) tiw for 3 weeks Up to three lesions < 2 cm ² each may be treated concurrently. Only one lesion 2-10 cm ² may be treated at a time.
Intravesical:	weekly:	<i>bladder cancer</i> ³⁰ <i>induction: 50 MU (with 1/3 vial BCG) weekly for 6 weeks</i> <i>maintenance: 50 MU (with 1/3 vial BCG) weekly for 3 consecutive weeks every 6 months</i>
Concurrent radiation ³ :		combination therapy must be given with care; interferons may be either radioprotective or radiosensitizing; life-threatening toxicities have occurred

BCCA usual dose noted in ***bold, italics***

- Dosage in myelosuppression:* modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix 6 "Dosage Modification for Myelosuppression"
- Dosage in renal failure*¹: risk of adverse reactions may be greater in patients with impaired renal function; adjustment may be necessary
- Dosage in hepatic failure:* modify according to protocol by which patient is being treated; if no guidelines available, the manufacturer suggests¹:

Indication	ALT/AST	Action
melanoma	> 5 x ULN	temporarily discontinue; restart at 50% once symptoms abate
melanoma	> 10 x ULN	discontinue
lymphoma	> 5 x ULN	discontinue

- Dosage in dialysis:* no specific guidelines found; in patients with hepatitis C undergoing chronic hemodialysis, interferon AUC was approximately double and clearance was approximately half that of patients with normal renal function³¹; interferon appears not to be removed by hemodialysis³

Children:

- Intravenous:* safety and effectiveness in pediatric patients have not been studied¹

REFERENCES:

- Schering Canada Inc. INTRON A® product monograph. Pointe Claire, Quebec; 23 December 2004.
- National Institute for Occupational Safety and Health (NIOSH). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati, Ohio: NIOSH - Publications Dissemination; 25 March 2004. p. 71-83.
- McEvoy GK, editor. AHFS 2005 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2005.
- Finley RS, Balmer C editors. Concepts in Oncology Therapeutics. 2nd ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 1998.
- Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clinical Pharmacology & Therapeutics 2000;68(5):556-67.
- Rose BD editor. Interferon alfa-2a: Drug Information. www.uptodate.com ed. Waltham, Massachusetts: UpToDate; 2005.
- Saba R, Jabbour E, Giles F, et al. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer 2005;103(12):2551-7.
- Christopher Lee MD. Personal Communication. BC Cancer Agency Lung Tumour Group; 22 January 2006.
- DeVita VT, Hellman S, Rosenberg SA. Cancer Principles & Practice of Oncology. 6th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2001. p. 2640.
- Leukemia/Bone Marrow Transplant Program of British Columbia. Leukemia/BMT Manual. 4th ed. Vancouver, British Columbia: Vancouver Hospital and Health Sciences Centre / BC Cancer Agency; 2003. p. 27.
- Sanofi-Synthelabo. RASBURICASE® product information. Markham, Ontario; 2004.
- Arnold TM, Reuter JP, Delman BS, et al. Use of single-dose rasburicase in an obese female. 2004;1428-31, 2004 Sep.
- Belldegrun AS, Franklin JR, O'Donnell MA, et al. Superficial bladder cancer: the role of interferon-alpha.[erratum appears in J Urol 1998 Oct;160(4):1444]. Journal of Urology. 1998;159(6):1793-801.
- Glashan RW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. Journal of Urology 1990;144(3):658-61.
- Lamm DL. Superficial bladder cancer. Current Treatment Options in Oncology 2002;3(5):403-411.
- Casato M, Pucillo LP, Leoni M, et al. Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity.[see comment]. American Journal of Medicine 1995;99(4):386-91.
- Sebastien Dao. Personal communication. Schering Canada; 2003.
- Desai RG. Drug interaction between alpha interferon and erythropoietin. J Clin Oncol 1991;9(5):893.
- Cassileth B, editor. Sho-saiko-to. Online publication: available at: <http://www.mskcc.org/mskcc/html/11571.cfm?RecordID=553&tab+HC#ref>: Memorial Sloan-Kettering Cancer Center; Accessed on 31 August 2005.

20. Rose BD. Theophylline Derivatives / Interferons. UpToDate, 2005. Available at: www.uptodate.com. Accessed 23 December 2005.
21. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
22. Schechter BA, Koreishi AF, Karp CL, et al. Long-term Follow-up of Conjunctival and Corneal Intraepithelial Neoplasia Treated with Topical Interferon Alfa-2b. *Ophthalmology* 2008;115(8):1291-1296.e1.
23. Ruiz L, Rodriguez I, Baez R, et al. Stability of an extemporaneously prepared recombinant human interferon alfa-2b eye drop formulation. *Am.J.Health-Syst Pharm.* 2007;64(16):1716-1719.
24. Department of Pharmacy. Extemporaneous Compounding Records: Interferon alfa-2b (Intron-A) 1 million units/mL. Miami, Florida, USA: Bascom Palmer Eye Institute; Undated.
25. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2004.
26. BC Cancer Agency Leukemia/BMT Tumour Group. BCCA Protocol Summary for Therapy of Chronic Myeloid Leukemia Using Interferon and Cytarabine. Vancouver: BC Cancer Agency; 2000.
27. B.C. Cancer Agency Lymphoma Tumour Group. BCCA Protocol Summary for Lymphoma palliative chemotherapy (LYPALL). Vancouver, British Columbia: BC Cancer Agency; 1 Nov 2002.
28. BC Cancer Agency Genitourinary Tumour Group. BCCA Protocol Summary for Alpha-Interferon (a-IFN) for Advanced Renal Cell Carcinoma. Vancouver: BC Cancer Agency; 2005.
29. BC Cancer Agency Melanoma Tumour Group. BCCA Protocol Summary for Adjuvant Therapy of High Risk Malignant Melanoma with High Dose Interferon (HDIFN) alfa-2b. Vancouver: BC Cancer Agency; 2005.
30. BC Cancer Agency Genitourinary Tumour Group. BCCA Protocol Summary for Palliative Therapy for BCG-Refractory Superficial High-Grade Transitional Cell Carcinoma Bladder with BCG and Interferon. Vancouver: BC Cancer Agency; 2005.
31. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. *Journal of the American Society of Nephrology* 1998;9(12):2344-8.